DOAC is sponsored by MCORRP as part of the Michigan Anticoagulation Quality Improvement Initiative (MAQI2). We invite your comments!
We have started monitoring why patients in the DOAC registry are stopping aspirin.
In the Follow-up only, Section 5: Medications, if any of the aspirin dosing choices (81mg, 162mg or 365mg) are to be “unchecked” because the aspirin was discontinued or stopped a “NOTE” will appear in blue:
The data form document has been updated. We have added specific questions regarding hematuria adverse events in the follow-up form. Download it here.
The document was revised, for dabigatran (all Indications) and rivaroxaban (all Indications except CAD & PAD) to add the following statement: “Consider alternative anticoagulation in patients who develop significant acute renal failure”
Page 3 of the document has been revised, for all DOACs, with the following “Not recommended as first-line therapy in patients with antiphospholipid antibody syndrome (APS)”.
